---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-001603"
form_type: "8-K"
ticker: "BICX"
cik: "0001443863"
company_name: "BioCorRx Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:29:26.587902+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCorRx acquires FDA-approved opioid withdrawal drug Lucemyra from USWM LLC

## Summary
- Upfront purchase price of $400,000 paid via seller retention of 50% of net sales and net distributable profits until capped.
- BioCorRx issued 500,000 shares of common stock and a warrant for 500,000 shares at $1.00 exercise price, 2-year term.
- Lucemyra is first and only non-opioid FDA-approved medication for opioid withdrawal; BioCorRx expects meaningful sales and positive cash flow.
- BioCorRx will pay a low single-digit royalty to USWM on future sales; no direct cash payment at closing.

## SEC filing metadata
- accession: 0001477932-25-001603
- form_type: 8-K
- ticker: BICX
- cik: 0001443863
- company_name: BioCorRx Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1443863/000147793225001603/0001477932-25-001603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1443863/000147793225001603/bicx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-001603
- JSON: https://secwatch.observer/filing/0001477932-25-001603.json
- Plain text: https://secwatch.observer/filing/0001477932-25-001603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.